Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer AND Carboplatin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    777 result(s) found for: Cancer AND Carboplatin. Displaying page 13 of 39.
    «« First « Previous 9  10  11  12  13  14  15  16  17  Next» Last»»
    EudraCT Number: 2022-002877-27 Sponsor Protocol Number: CTRIAL-IE-21-29/NRG-GY019 Start Date*: 2023-07-06
    Sponsor Name:Cancer Trials Ireland
    Full Title: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or P...
    Medical condition: Primary low-grade serous carcinoma of the ovary or peritoneum.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007107 Cancer of ovary LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026340 Malignant neoplasm of peritoneum, unspecified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000851-15 Sponsor Protocol Number: M19CVT Start Date*: 2020-01-16
    Sponsor Name:NKI-AVL
    Full Title: Treatment of metastatic vulvar carcinoma in a neoadjuvant setting with Carboplatin and Paclitaxel chemotherapy
    Medical condition: vulvar carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047750 Vulval neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000913-13 Sponsor Protocol Number: H3E-MC-S095 Start Date*: 2007-06-28
    Sponsor Name:Lilly S.A.
    Full Title: Phase 2 Study of Concurrent Carboplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung Cancer Estudio Fase II de terapia concurrente con Carboplatino, Pemetrexed y Radioterapia pa...
    Medical condition: Pacientes con diagnóstico histopatológico o citológico de cáncer de pulmón microcítico estadio limitado que no han recibido quimioterapia o radioterapia previa.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041069 Small cell lung cancer limited stage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003389-26 Sponsor Protocol Number: RG14-093 Start Date*: 2015-01-12
    Sponsor Name:University of Birmingham
    Full Title: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
    Medical condition: Oropharyngeal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031096 Oropharyngeal cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020966-34 Sponsor Protocol Number: ICORG10-05 Start Date*: 2010-08-06
    Sponsor Name:ICORG
    Full Title: A phase II neoadjuvant study assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Traztuzumab and Lapatinib) in Erb B2 positive breast cancer patients
    Medical condition: Her 2 positive locally advanced or primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022273-34 Sponsor Protocol Number: CRAD001KDE37 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A multi-centric, open-label, phase II study investigating the combination of Afinitor with paclitaxel and carboplatin in first line treatment of patients with advanced (stage IV) large cell lung c...
    Medical condition: large-cell neuroendocrine carcinoma of the lung
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004526-90 Sponsor Protocol Number: TaxErb-1 Start Date*: 2007-01-30
    Sponsor Name:Klinik Löwenstein gGmbH
    Full Title: TaxErb-Protokoll; Docetaxel-Carboplatin Chemotherapie in Kombination mit Cetuximab bei Patienten mit local fortgeschrittenem oder metastasiertem, nicht-kleinzelligem Bronchial-Karzinom (NSCLC)-ein ...
    Medical condition: Patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066490 Progression of non small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002860-42 Sponsor Protocol Number: MITO25 Start Date*: 2017-09-25
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in patients with advanced (stage III B-C-IV) ov...
    Medical condition: Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006888 Ca ovary LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-007520-17 Sponsor Protocol Number: 800088NAP2001 Start Date*: 2008-07-25
    Sponsor Name:Janssen-Cilag International N.V, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Effect of RWJ-800088 on The Prevention of Chemotherapy-Induced Anemia and The Prevention of Chemotherapy-Induced Thromb...
    Medical condition: Chemotherapy induced anaemia and chemotherapy induced thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10039884 Secondary thrombocytopenia LLT
    9.1 10054606 Secondary anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000634-33 Sponsor Protocol Number: D967SC00001 Start Date*: 2021-11-02
    Sponsor Name:ASTRAZENECA AB
    Full Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harb...
    Medical condition: Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084787 HER2 mutant non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003048-28 Sponsor Protocol Number: BO44426 Start Date*: 2023-03-01
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF DIVARASIB IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATED...
    Medical condition: Untreated Advanced or Metastatic Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000250-35 Sponsor Protocol Number: WO30070 Start Date*: 2016-06-16
    Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE I...
    Medical condition: Urothelial Carcinoma, locally advanced or metastatic
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Completed) EE (Completed) GR (Completed) PL (Completed) SI (Completed) GB (GB - no longer in EU/EEA) FI (Completed) NL (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001859-43 Sponsor Protocol Number: CA209-743 Start Date*: 2016-11-04
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma
    Medical condition: Untreated unresectable Pleural Mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) NL (Completed) BE (Completed) DE (Completed) FR (Completed) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004076-19 Sponsor Protocol Number: ENGOT-cx1/BGOG-cx1 Start Date*: 2013-10-28
    Sponsor Name:UZ Leuven / Belgian Gynaecological Oncology Group
    Full Title: ENGOT-cx1/BGOG-cx1: "Randomized double-blind Phase II study comparing 3-weekly carboplatin (AUC 5) + paclitaxel 175 mg/m2 with or without concomitant and maintenance nintedanib (NINTEDANIB) in adv...
    Medical condition: Advanced or recurrent cervical carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000711-85 Sponsor Protocol Number: MEF4984g Start Date*: 2011-10-17
    Sponsor Name:Genentech, Inc
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF MEGF0444A IN COMBINATION WITH CARBOPLATIN, PACLITAXEL AND BEVACIZUMAB IN PATIENTS ...
    Medical condition: ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025052 Lung cancer non-small cell stage III LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025048 Lung cancer non-small cell recurrent LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025051 Lung cancer non-small cell stage II LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025046 Lung cancer cell type unspecified stage IV LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025053 Lung cancer non-small cell stage IIIA LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025050 Lung cancer non-small cell stage I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003466-34 Sponsor Protocol Number: M06OVH Start Date*: 2006-12-14
    Sponsor Name:NKI-AVL
    Full Title: Phase III randomised clinical trial for stage III ovarian carcinoma randomising between secondary debulking surgery with or without hyperthermic intraperitoneal chemotherapy (OVHIPEC-I)
    Medical condition: ovarian carcinoma or peritoneal cancer (PPSC) or fallopian tube carcinoma FIGO Stage III
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003474-35 Sponsor Protocol Number: 16-214-05 Start Date*: 2020-02-13
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab with or without Chemotherapy in Patients wit...
    Medical condition: Patients with with locally advanced or metastatic solid tumors.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004207-39 Sponsor Protocol Number: AGO-OVAR2.34 Start Date*: 2021-06-07
    Sponsor Name:AGO Research GmbH
    Full Title: A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. supported by: DIAGNOSTIC ...
    Medical condition: This trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-ba...
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016182 Fallopian tube cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004331-37 Sponsor Protocol Number: BO40336 Start Date*: 2018-06-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS...
    Medical condition: Completely resected, Stage IB (tumors ≥4 cm) to Stage IIIA, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) GR (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Completed) PL (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002742-32 Sponsor Protocol Number: Toco-Pulm Start Date*: 2015-11-27
    Sponsor Name:Vejle Hospital
    Full Title: Tocotrienol as a nutritional supplement in patients with advanced pulmonal cancer
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10025044 Lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 9  10  11  12  13  14  15  16  17  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 01 16:39:43 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA